Table 1.
Information of gene expression datasets used in this study
| Dataset* | GEO access number or web location | Number of patients | % DFS data available | % OS data available | Reference |
|---|---|---|---|---|---|
| 1 | GSE1456 | 159 | 100 | 100 | (22) |
| 2 | GSE2603 | 99 | 82.8 | 0 | (23) |
| 3 | GSE6532 | 327 | 96.0 | 0 | (24) |
| 4 | GSE3494 | 108& | 100 | 100 | (25) |
| 5 | GSE7390 | 198 | 100 | 100 | (26) |
| 6 | GSE11121 | 197 | 100 | 0 | (27) |
| 7 | GSE12093 | 136 | 100 | 0 | (28) |
| 8 | GSE2034 | 286 | 100 | 0 | (29) |
| 9 | ArrayExpress: E-TABM-158 | 130 | 99.2 | 99.2 | (30) |
| 10 | NKI (http://microarray-pubs.stanford.edu/wound_NKI/) | 295 | 100 | 100 | (31) |
| 11 | GSE17080 | 185 | 0 | 0 | (32) |
| 12 | GSE3744 | 47 | 0 | 0 | (33) |
*
Dataset 1 to 9, 11 and 12 are profiled using Affymetrix microarray, Dataset 11 using Agilent Oligo microarray. Dataset 1–10 are used to evaluate prognostic impact of FBXW7 expression. Dataset 1–10 was used for analysis of disease-free survival in Figure 2, 3, 5 and 6. Dataset 1, 4, 5, 9 and 10 was used for analysis of overall survival in Figure 2, 3, 5 and 6. Dataset 11 and 12 contains both normal and breast cancer samples.